These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16490679)

  • 1. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA; Malcy JA; Saxon AJ
    J Subst Abuse Treat; 2006 Mar; 30(2):159-63. PubMed ID: 16490679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with complicated buprenorphine inductions.
    Whitley SD; Sohler NL; Kunins HV; Giovanniello A; Li X; Sacajiu G; Cunningham CO
    J Subst Abuse Treat; 2010 Jul; 39(1):51-7. PubMed ID: 20682186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methadone Withdrawal-Induced Psychosis: A Case Report.
    Oke O; Sekh MB; Johnson BO; Adeyemo S
    Cureus; 2024 Feb; 16(2):e55256. PubMed ID: 38558723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caregiver Perception, Self-efficacy, and Knowledge of Methadone Tapers for Children With Iatrogenic Opioid Abstinence Syndrome.
    Capino AC; Miller JL; Hughes KM; Miller MJ; Johnson PN
    J Pharm Technol; 2016 Jun; 32(3):104-115. PubMed ID: 34860963
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services?
    White E; Read J; Julo S
    Ther Adv Psychopharmacol; 2021; 11():2045125320981174. PubMed ID: 33520155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapering and discontinuation of methadone for chronic pain.
    Breivik H
    J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):185-6. PubMed ID: 26095495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological strategies for detoxification.
    Diaper AM; Law FD; Melichar JK
    Br J Clin Pharmacol; 2014 Feb; 77(2):302-14. PubMed ID: 24118014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Ward HB; Barnett BS; Suzuki J
    Subst Abus; 2019; 40(2):140-145. PubMed ID: 30888254
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose Tapering Strategy for Heroin Abstinence among Methadone Maintenance Treatment Participants: Evidence from A Retrospective Study in Guangdong, China.
    Lu Q; Zou X; Liu Y; Gong C; Ling L
    Int J Environ Res Public Health; 2019 Aug; 16(15):. PubMed ID: 31390750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of gabapentin dose in treatment of opioid withdrawal.
    Salehi M; Kheirabadi GR; Maracy MR; Ranjkesh M
    J Clin Psychopharmacol; 2011 Oct; 31(5):593-6. PubMed ID: 21869694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
    Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
    Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A stage I pilot study of acceptance and commitment therapy for methadone detoxification.
    Stotts AL; Green C; Masuda A; Grabowski J; Wilson K; Northrup TF; Moeller FG; Schmitz JM
    Drug Alcohol Depend; 2012 Oct; 125(3):215-22. PubMed ID: 22425411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapering from methadone maintenance: attitudes of clients and staff.
    Gold ML; Sorensen JL; McCanlies N; Trier M; Dlugosch G
    J Subst Abuse Treat; 1988; 5(1):37-44. PubMed ID: 3361625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes.
    Jones HE; O'Grady KE; Malfi D; Tuten M
    Am J Addict; 2008; 17(5):372-86. PubMed ID: 18770079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial.
    Moghadam MS; Alavinia M
    Pak J Pharm Sci; 2013 Sep; 26(5):985-9. PubMed ID: 24035957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Goals of Youths in Canada Receiving Medication-Assisted Treatment for Opioid Use Disorder.
    Chai D; Rosic T; Panesar B; Sanger N; van Reekum EA; Marsh DC; Worster A; Thabane L; Samaan Z
    JAMA Netw Open; 2021 Aug; 4(8):e2119600. PubMed ID: 34351402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.
    Krawczyk N; Williams AR; Saloner B; Cerdá M
    J Subst Abuse Treat; 2021 Jul; 126():108329. PubMed ID: 34116820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Narrative Review of Third-Wave Cognitive-Behavioral Therapies in Addiction.
    Balandeh E; Omidi A; Ghaderi A
    Addict Health; 2021 Jan; 13(1):52-65. PubMed ID: 33995960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications.
    Framer A
    Ther Adv Psychopharmacol; 2021; 11():2045125321991274. PubMed ID: 33796265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.